Literature DB >> 15871119

Respiratory syncytial virus load predicts disease severity in previously healthy infants.

John P DeVincenzo1, Chadi M El Saleeby, Andrew J Bush.   

Abstract

BACKGROUND: Elucidating the relationship between viral load and respiratory syncytial virus (RSV) disease severity is critical to understanding pathogenesis and predicting the utility of antivirals.
METHODS: Previously healthy, naturally RSV-infected infants <24 months old not treated with ribavirin, passive antibody, or corticosteroids were prospectively studied (n=141). Viral loads were measured by fresh quantitative culture from nasal washes collected at a single time point shortly after hospitalization.
RESULTS: The subjects' mean age was 112.1 days, and the mean estimated gestational age at birth was 38.38 weeks. RSV load decreased with longer durations of symptoms before specimen collection (P=.01). Male subjects had higher RSV loads than female subjects (P=.036). Significant independent predictors of longer hospitalization were congenital anomaly (P<.0001), lower weight on admission (P=.028), and higher nasal RSV load (P=.008). A 1-log higher RSV load predicted a 0.8-day longer hospitalization. Lower weight and higher RSV load were also independently associated with respiratory failure (P<.0005 and P=.0049, respectively) and requirement for intensive care (P=.0007 and P=.0048, respectively).
CONCLUSIONS: In previously healthy infants, higher RSV loads measured at capturable time points after symptom onset predict clinically relevant measures of increased disease severity.

Entities:  

Mesh:

Year:  2005        PMID: 15871119     DOI: 10.1086/430008

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  107 in total

1.  Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics.

Authors:  Jessica W Lau; Young-In Kim; Ryan Murphy; Ruchi Newman; Xiao Yang; Michael Zody; John DeVincenzo; Yonatan H Grad
Journal:  Virology       Date:  2017-08-03       Impact factor: 3.616

2.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Elevated Levels of Type 2 Respiratory Innate Lymphoid Cells in Human Infants with Severe Respiratory Syncytial Virus Bronchiolitis.

Authors:  Luan D Vu; David Siefker; Tamekia L Jones; Dahui You; Ryleigh Taylor; John DeVincenzo; Stephania A Cormier
Journal:  Am J Respir Crit Care Med       Date:  2019-12-01       Impact factor: 21.405

Review 4.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

5.  Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Authors:  Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo
Journal:  Pediatr Res       Date:  2017-08-09       Impact factor: 3.756

6.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

7.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

8.  A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants.

Authors:  Michaël V Lukens; Alma C van de Pol; Frank E J Coenjaerts; Nicolaas J G Jansen; Vera M Kamp; Jan L L Kimpen; John W A Rossen; Laurien H Ulfman; Carline E A Tacke; Marco C Viveen; Leo Koenderman; Tom F W Wolfs; Grada M van Bleek
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 9.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.